Work

Case study for the integrated approaches for testing and assessment forAOP3-based risk assessment of tebufenpyrad, concerning mitochondrial complex I inhibition mediated neurotoxicity

Year: 2026
Type: article
Abstract: The OECD-endorsed Adverse Outcome Pathway number 3 (AOP3) links inhibition of the mitochondrial complex I of nigro-striatal neurons to the Adverse Outcome (AO896) Parkinsonian motor deficits. This AOP3-based Integrated Approaches to Testing and Assessment (IATA) case study explores the applicability of an in vitro test battery (IVB) measuring the molecular initiating event (MIE) and key events (KEs) along AOP3 for testing and characterising mitochondrial Complex I inhibition-mediated Parkinsonian neurodegeneration, and supporting chemical risk assessment in the pesticides area. AOP 3 (“Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits”) starts with the Molecular Initiating Event (MiE888), that is Binding of inhibitor to NADH-ubiquinone oxidoreductase (complex I) and its consequent Inhibition (Key Event, KE887) in adult brain. Inhibition of mitochondrial Complex I results in Mitochondrial dysfunction (KE177) and consequently Impaired, Proteostasis (KE889), which leads to a subsequent Degeneration of dopaminergic neurons of the nigrostriatal pathway (KE890) associated with the AO896 (Parkinsonian motor deficits). To date, AOP3 has been investigated quantitatively and experimentally in an in vitro battery, i.e. AOP3-IVB, using 21 substances known to be mitochondrial inhibitors due to their pesticidal Mode of Action (MoA). The AOP3-IVB has been specifically designed to assess in vitro biomarkers of early effects related to the MiE and several KEs of AOP3. The AOP3-IVB consists of a series of in vitro assays using Lund human mesencephalic (LUHMES) cells (i.e. immortalized human neuronal precursors, differentiated into dopaminergic neurons) to test for MiE888 and KE887, KE177 and KE890. In this AOP-based IATA, bioactivity in the AOP3-IVB was used as a proxy for in vivo dopaminergic neuron degeneration in the substantia nigra pars compacta (SNpc) consequent to binding to and inhibition of mitochondrial Complex I. An IATA case study workflow was designed according to the current European Pesticide Regulation (EU) 283/2013 and 1107/2009, using the OECD IATA Template 2025 and with a single chemical risk assessment problem formulation for chronic neurotoxicity. The core elements of the case study workflow were: (1) estimation of the internal exposure at the target tissue (i.e., the brain) from external exposure estimates for the relevant routes of exposure (mainly dermal and respiratory for operator, worker and residents as well as incidental oral for children residents) through the generation of in vitro data and the development of a Physiologically-Based Kinetic (PBK) Model (published in Henri et al., 2023); (2) the derivation of an in vitro AOP-3 based PoD via the development of methods and the generation of experimental data to empirically support the AOP3 in the AOP3-IVB (published in Alimohammadi et al., 2023); and (3) the performance by the EFSA Neurotoxicity Working Group of an independent uncertainty analysis for each line of evidence, the integration of these lines of evidence and related uncertainties and the derivation of an uncertainty distribution for the Margin of Internal Exposure (MoIE). A probabilistic approach was adopted to quantify the uncertainties in the two parameters (i.e. the internal concentration estimate and the AOP3-based PoD) to be combined for the derivation of a MoIE uncertainty distribution. The insecticide tebufenpyrad, a complex I inhibitor of the mitochondrial electron transport chain (ETC), was selected as a model chemical. This stepwise approach was employed to explore how the active substance tebufenpyrad may contribute to the risk of developing the AO, Parkinsonian syndrome as a consequence of dopaminergic neuron degeneration in Substantia Nigra pars compacta (SNpc) due to mitochondrial toxicity. Overall, the results of the AOP3-based IATA indicate that, the AOP3-IVB could be used to identify and characterize Tebufenpyrad mitochondrial Complex I inhibition-mediated neurotoxicity (in vitro) and to define an in vitro AOP-based biomarker that is applicable as a Point of Departure (PoD) for risk assessment. The lowest concentration of Tebufenpyrad (in nM) affecting neurite area in LUHMES cells was selected as in vitro PoD in this case study. Overall, these findings indicate that the lowest concentration of Tebufenpyrad capable of reducing the neurite area in LUHMES cells ranges between 3 and 40 nM, with a probability of around 0.9 that the lowest concentration of Tebufenpyrad affecting neurite area in LUHMES cells (considered a proxy of KE890) is between 3 and 27nM. The most relevant uncertainties considered in this exercise were related to the physico-chemical characteristics of Tebufenpyrad that made it difficult to estimate the in vitro free chemical fraction reaching the intracellular target, as well as the selected assay and in vitro test system used to measure KE890 as a proxy for in vivo neurodegeneration of dopaminergic neurons of the nigrostriatal pathway, ultimately informing the AO for pesticide neurotoxicity risk assessment. In addition, the case study demonstrates that an in vitro based PBK model could be developed to estimate internal brain exposure, enabling calculation of the MoIE from an in vitro PoD. It was concluded that under the conditions of use as a plant protection product, the highest plausible level of human brain concentration is almost certainly within the credible interval of [0.02, 13.86] μM (20, 13860 nM) for operators not using protective measures (worst-case scenario). Overall, the experts assigned a probability of around 96% that the (average) steady state concentration (Css) of Tebufenpyrad in the brain of such operators was between 0.02 and 5.556 μM (20 and 5556 nM). The most relevant uncertainties of using the PBK model to predict internal brain exposure and consequently the MoIE are due to the physico-chemical characteristics of tebufenpyrad, the selected PBK model and the platform used including missing information on the applicability domain, on the available input parameters and the lack of validation of the PBK model through appropriate in vivo radiolabelled absorption, distribution, metabolism and excretion (ADME) studies. Based on the distribution of the PBK-modelled estimates relative to the highest concentration of brain exposure relative to the distribution of the lowest concentration affecting neurite area as a proxy of KE890, there is a 99.7% probability that the MoIE is below 1 for unprotected operators. This may indicate a potential concern of degeneration of dopaminergic neurons that can potentially result Parkinsonian syndrome neurodegeneration for unprotected operators. This population was included in this IATA case study problem formulation since it is likely to be the most exposed compared to the other exposed populations described in Henri et al., (2023), i.e. operators with PPE, workers and residents (adults and children). These conclusions are based on the most conservative estimates for an in vitro PoD and for an internal exposure calculation derived from a NAM-based PBK model and are associated with significant uncertainty. Understanding the impact of these assumptions and uncertainties on the outcome would require a further iterative approach and/or data generation. The case study thoroughly and systematically illustrates the uncertainties of using an in vitro PoD and an in vitro-based PBK model for pesticides risk assessment. It also supports the current applicability of AOP3 in the context of regulatory risk assessment. Importantly, the structured uncertainty analysis applied in this case study could inform future refinement of the AOP3-IVB, support the development of AOP-linked test methods and improvements in PBK modelling, and contribute to a broader implementation of in vitro methods in chemical risk assessment. This case study was developed with contributions from the following scientists:Irene Cattaneo1, Andrea Terron2, Laura Martino1, Adeline Cavelier 2,4, Kevin Crofton2, Antonio Hernandez-Jerez2, Helena Hoegberg-Durdock2, Carsten Kneuer2, Emily A. McVey2, Bertrand Desprez4, Jérome Henri4, Ludovic Le Hegarat4, Alicia Paini1, Jochem Louisse3, Rafaela Rodrigues de Jesus3, Marcel Leist5, Mahshid Alimohammadi5, Anna-Katharina Holzer5, Tanja Burgdorf, Anna F. Castoldi, Annamaija Suontausta3, Iris Mangas3 1.Methodology and Scientific Support Unit, European Food Safety Authority, EFSA2.Neurotoxicity Working Group, European Food Safety Authority, EFSA3.Pesticides Peer Review Unit, European Food Safety Authority, EFSA4.Agence nationale de sécurité sanitaire, ANSES5.Universität Konstanz, UKN Corresponding authors:Iris Mangas : [email protected]; Irene Cattaneo : [email protected]
Language: English
Subfield: Small Animals
Field: Veterinary
Open Access status: green
OpenAlex ID: W7236695852
Cites:
Cited by:
Related to: 10